
CLB • NYSE
Unlock comprehensive alternative data signals to make better investment decisions

Track website visits, page views, unique visitors, and engagement metrics over time to gauge online interest and brand strength.

Monitor Twitter follower growth, engagement rates, and social media presence to understand brand reach and community sentiment.

Analyze TikTok follower trends and viral content performance to measure youth demographic appeal and cultural relevance.

Track Facebook page likes, comments, shares, and post engagement to assess community interaction and brand loyalty.

Monitor Instagram follower growth, engagement rates, and visual content performance across demographics.

Track YouTube channel growth, video views, and subscriber engagement to measure content marketing effectiveness.

Monitor LinkedIn company page followers and professional network growth to assess B2B brand strength and talent attraction.

Track open job positions and hiring trends as a leading indicator of company expansion, contraction, or strategic shifts.

Monitor employee headcount changes on LinkedIn to gauge organizational growth, restructuring, or cost-cutting measures.

Analyze sentiment scores from Reddit discussions to understand retail investor mood and potential price momentum.

Track daily news mentions across major publications to measure media attention, PR effectiveness, and market awareness.

View key financial metrics including Revenue, Net Income, EPS, Free Cash Flow, EBITDA, and Total Assets. Access 2-year quarterly charts for Revenue & Income and Free Cash Flow trends.

Analyze technical indicators including 50-day Simple Moving Average (SMA) with price overlay and Relative Strength Index (RSI) charts.
TrendEdge provides tools and data for research and educational purposes only and does not provide investment advice or personal recommendations.
You don't hold CLB in your mock portfolio yet.
With EPS at 0.68 and a PE ratio of 23.57, Core Laboratories is priced at a moderate earnings multiple that suggests the market expects stable but not explosive growth. Profitability appears positive but not exceptional relative to the valuation, implying that current earnings are adequately, but not cheaply, reflected in the share price. In the absence of clear revenue or margin acceleration data, the financial picture leans toward steady rather than strongly improving.
The stock trades at $16.03, modestly above its 200‑day moving average of $12.96, indicating a longer‑term uptrend despite a 2.8% pullback over the last month. An RSI of 51.18 is essentially neutral, showing neither overbought nor oversold conditions. Overall, the technical setup suggests a consolidating uptrend rather than a clear bullish breakout or bearish breakdown.
Website traffic is flat month over month, suggesting no recent acceleration in digital engagement. The drop to zero job openings is a negative signal, potentially pointing to hiring freezes, cost controls, or limited near‑term growth initiatives. Social media followings are small and growing only marginally, with slight declines on YouTube, indicating muted brand momentum and limited evidence of expanding commercial reach.
Core Laboratories shows a technically constructive longer‑term trend and reasonable profitability, but alternative data point to a cautious operational stance and limited growth momentum. The valuation is not clearly cheap given the modest earnings profile, while hiring and engagement signals do not yet support a strong growth narrative. Overall, the stock setup appears balanced between positives and negatives, leading to a neutral outlook.
Our AI Score rates companies on a scale from 0 to 10, based on alternative data points such as web traffic, app downloads, and job postings — combined with financial health indicators and technical signals.
Key moves vs recent baseline (last day / last week)
Plain-English summary of the biggest drivers (informational)
Potential risk factors to review
Based on earnings timing, volatility, liquidity and crowd activity. Informational signals only — not investment advice.
Reassess your thesis if any of these occur: